
Fortress Biotech, Inc.: quarterly results
Price
$1.74
November 16, 2026Market cap $54M
What Ploutos Investor adds for Fortress Biotech
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 37% since Aug 13, 2026, when the 10-Q these figures come from was filed ($2.98 then, $1.88 on Nov 13, 2026). The figures date from before that move.10-Q
- The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
- A figure that did not match the numbers it is built from has been left out.
Results, quarter by quarter
When the company put out each quarter's results (its 8-K, item 2.02), what they showed against the same quarter a year before, and how the stock moved on the first session after.
Next results
last Nov 13, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
The first session after results
±5.9%average move, either way
1 times upof the last 43 times down
Largest: -11.5% on Apr 1, 2026 (Q4 2025).
How the stock moved after each release
The close of the first session after the results against the close before them.
FBIO that sessionS&P 500 the same day
Every release
Revenue and diluted EPS of the quarter reported, with the change against the same quarter a year before.
- Q3 2026Stock, next session-5.5%
- Q2 2026Stock, next session-1.7%
- Q1 2026Stock, next session+4.8%
- Q4 2025Stock, next session-11.5%
| Quarter | Released | Revenue | EPS | Stock, next session | S&P 500 | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 13, 2026before the close | $19M+8.7% | -$0.23-309.1% | -5.5% | -0.4% | 8-K |
| Q2 2026 | Aug 13, 2026after the close | $19M+14.0% | -$0.08-117.8% | -1.7% | -0.2% | 8-K |
| Q1 2026 | May 14, 2026after the close | $16M+22.1% | $2.82 | +4.8% | -1.2% | 8-K |
| Q4 2025 | Mar 31, 2026after the close | $16M+6.3% | -$0.15 | -11.5% | +0.7% | 8-K |
Every release
FBIO's results days and the share's move after each, from Q1 2012 to Q3 2025, 56 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 8 quarters.
and 51 more, back to Q1 2012
Times are the SEC's acceptance of the 8-K, in New York time: before 16:00 the market traded on it that day, after it the next day. A move on a results day has other causes too, and says nothing about the next one.
The full analysis
What do Fortress Biotech's filings show?
The results say what Fortress Biotech reported. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.